摘要
重症肌无力(myasthenia gravis,MG)是常见的抗体介导的、细胞免疫依赖及补体参与的神经-肌肉接头免疫疾病.其治疗主要包括药物治疗(症状性治疗、非特异性免疫抑制治疗、靶向免疫治疗)、免疫调节(静脉注射用人免疫球蛋白与血浆置换)及胸腺切除术.随着对MG治疗研究的不断深入,靶向B细胞、补体系统及新生儿Fc受体等特异性免疫调节成为目前治疗MG的研究热点.与传统免疫抑制剂相比,MG患者对新型生物制剂耐受性较好,现就MG靶向治疗相关药物的研究进行阐述,并总结其在MG治疗中的疗效及安全性,旨在寻找更多的治疗方案.
Abstract
Myasthenia gravis(MG)is a common antibody mediated,cell-mediated,and complement dependent neuromuscular junction immune disease.The treatment mainly includes drug therapy(symptomatic therapy,non-specific immunosuppressive therapy,targeted immunotherapy),immune regulation(intravenous injection of human immunoglobulin and plasma exchange),and thymectomy.With the continuous deepening of research on MG treatment,targeted immune regulation of B cells,complement system,and neonatal Fc receptors has become a current research hotspot in the treatment of MG.Compared with traditional immunosuppressants,MG patients have better tolerance to new biological agents.This article elaborates on the research of MG targeted therapy related drugs and summarizes their efficacy and safety in MG treatment,aiming to find more treatment options.
NETL
NSTL
万方数据